TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

Takeda

ImmunologyOncologyGastroenterology
Big Pharma

Takeda is a major pharmaceutical company focused on Immunology, Oncology, Gastroenterology. Key products include ENTYVIO.

1945
Since
68
Drugs
-
Trials
27
Approved (2yr)

Key Drugs

ENTYVIO
vedolizumab
Immunology
Integrin alpha4beta7 2 indications · 2014
LIVTENCITY
maribavir
2 indications · 2021
ICLUSIG
ponatinib hydrochloride
ABL 2 indications · 2012
GATTEX KIT
teduglutide
GLP-2R 1 indications · 2012
NESINA
alogliptin benzoate
DPP-4 1 indications · 2013

Recent Activity

LIVTENCITY 2025-11-21
Efficacy
ICLUSIG 2025-10-10
Efficacy
ADDERALL XR 10 2025-09-23
Labeling
VYVANSE 2025-09-23
Labeling
VYVANSE 2025-09-23
Labeling
GATTEX KIT 2025-09-05
Labeling
GATTEX KIT 2025-08-13
REMS
MOTEGRITY 2025-07-10
Efficacy
FRUZAQLA 2025-02-28
Labeling
GATTEX KIT 2024-09-19
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Immunology 40%
3 drugs Phase 3: 41 Phase 2: 11 Phase 1: 16
Oncology 22%
6 drugs Phase 3: 6 Phase 2: 15 Phase 1: 32
Gastroenterology 21%
4 drugs Phase 3: 16 Phase 2: 6 Phase 1: 14
Neurology 9%
1 drugs Phase 3: 8 Phase 2: 5 Phase 1: 3
Metabolic 8%
3 drugs Phase 3: 4 Phase 1: 10

Pipeline Strength Pro

Loading...

Competitors Pro

Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Amgen biotech
Oncology, Immunology, Metabolic, Gastroenterology, Neurology
EMD SERONO INC biotech
Oncology, Neurology, Immunology, Metabolic, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Neurology
Pfizer big-pharma
Oncology, Immunology, Gastroenterology